The prognostic value of CDH3, predictive of shorter OS in independent cohorts of GBM patients (Fig. 5 and Tables 2 and 3), is concordant with the results obtained in vivo, and fits well with previous reports in breast cancer [19, 40] and lung cancer [39]. This evidence concerns the gene CDH3 and glioblastoma.